Two Sigma Investments’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$231M Buy
6,286,501
+5,943,310
+1,732% +$282M 0.19% 118
2025
Q4
$17.5M Sell
343,191
-1,348,335
-80% -$68.9M 0.02% 791
2025
Q3
$93.9M Sell
1,691,526
-525,424
-24% -$30.8M 0.14% 201
2025
Q2
$153M Sell
2,216,950
-930,979
-30% -$63.3M 0.27% 89
2025
Q1
$219M Buy
3,147,929
+1,303,506
+71% +$108M 0.47% 35
2024
Q4
$159M Buy
+1,844,423
New +$199M 0.35% 60
2024
Q1
Sell
-21,600
Closed -$2.23M 3269
2023
Q4
$2.23M Sell
21,600
-30
-0.1% -$2.97K 0.01% 1450
2023
Q3
$1.97M Sell
21,630
-641,704
-97% -$56.5M 0.01% 1395
2023
Q2
$53.7M Buy
663,334
+602,682
+994% +$49.2M 0.13% 199
2023
Q1
$4.83M Buy
60,652
+42,652
+237% +$3.02M 0.01% 933
2022
Q4
$1.22M Buy
+18,000
New +$1.06M ﹤0.01% 1599
2022
Q3
Sell
-256,334
Closed -$14.3M 2708
2022
Q2
$14.3M Buy
256,334
+38,768
+18% +$2.15M 0.05% 408
2022
Q1
$12.1M Sell
217,566
-453,564
-68% -$23.3M 0.04% 546
2021
Q4
$37.6M Sell
671,130
-879,068
-57% -$47.6M 0.08% 301
2021
Q3
$74.4M Buy
1,550,198
+630,348
+69% +$30.5M 0.17% 145
2021
Q2
$38.5M Buy
919,850
+19,772
+2% +$766K 0.09% 270
2021
Q1
$30.3M Sell
900,078
-203,952
-18% -$7.26M 0.08% 293
2020
Q4
$38.6M Buy
1,104,030
+144,090
+15% +$4.98M 0.11% 208
2020
Q3
$33.3M Sell
959,940
-407,050
-30% -$13.6M 0.12% 179
2020
Q2
$44.8M Buy
1,366,990
+750,002
+122% +$23.9M 0.22% 89
2020
Q1
$18.6M Sell
616,988
-327,532
-35% -$9.75M 0.15% 137
2019
Q4
$27.3M Buy
944,520
+93,140
+11% +$2.58M 0.08% 284
2019
Q3
$22M Buy
851,380
+621,826
+271% +$15.7M 0.07% 327
2019
Q2
$5.86M Sell
229,554
-441,734
-66% -$10.9M 0.02% 822
2019
Q1
$17.6M Sell
671,288
-641,750
-49% -$15.8M 0.06% 441
2018
Q4
$30.2M Buy
1,313,038
+7,416
+0.6% +$165K 0.12% 229
2018
Q3
$30.8M Buy
1,305,622
+1,116,460
+590% +$27.2M 0.08% 315
2018
Q2
$4.36M Buy
+189,162
New +$4.5M 0.01% 1092
2017
Q2
Sell
-1,601,944
Closed -$27.5M 3188
2017
Q1
$27.5M Buy
1,601,944
+199,766
+14% +$3.48M 0.09% 291
2016
Q4
$25.1M Buy
1,402,178
+568,322
+68% +$10.3M 0.1% 245
2016
Q3
$17.3M Buy
833,856
+816,100
+4,596% +$20.2M 0.06% 353
2016
Q2
$477K Buy
+17,756
New +$487K ﹤0.01% 2283
2015
Q3
Sell
-96,014
Closed -$2.63M 2561
2015
Q2
$2.63M Buy
+96,014
New +$2.7M 0.01% 1044
2015
Q1
Sell
-251,342
Closed -$5.32M 2783
2014
Q4
$5.32M Buy
+251,342
New +$5.61M 0.03% 625
2014
Q2
Sell
-93,962
Closed -$2.15M 2293
2014
Q1
$2.15M Buy
93,962
+53,212
+131% +$1.13M 0.01% 915
2013
Q4
$753K Sell
40,750
-595,460
-94% -$10.4M ﹤0.01% 1464
2013
Q3
$10.8M Buy
636,210
+605,460
+1,969% +$10.2M 0.07% 340
2013
Q2
$477K Buy
+30,750
New +$512K ﹤0.01% 1436

Other funds holding NVO

Two Sigma Investments's NVO Position: Q1 2026 in Review

Two Sigma Investments increased its Novo Nordisk (NVO) stake by 1,732% in Q1 2026, buying an estimated $282M and bringing the position to 6,286,501 shares worth $231M. The position accounts for 0.19% of the portfolio, ranked #118.

Two Sigma Investments first reported a position in NVO in Q2 2013 and has held it in 38 quarters since. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Two Sigma Investments held 6,286,501 shares of Novo Nordisk worth $231M as of Q1 2026.
  • Two Sigma Investments bought 5,943,310 Novo Nordisk shares in Q1 2026, an estimated $282M.
  • Novo Nordisk made up 0.19% of Two Sigma Investments's portfolio in Q1 2026, its #118 holding.
  • Two Sigma Investments first reported a position in Novo Nordisk in Q2 2013 and has held it in 38 quarters since.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.